Urogen Pharma (NASDAQ:URGN) has earned an average broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and three have given a strong buy rating to the company.

Brokerages have set a twelve-month consensus target price of $28.00 for the company and are anticipating that the company will post ($2.40) EPS for the current quarter, according to Zacks. Zacks has also assigned Urogen Pharma an industry rank of 165 out of 265 based on the ratings given to its competitors.

URGN has been the topic of a number of analyst reports. Cowen and Company initiated coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They set an “outperform” rating on the stock. Jefferies Group LLC initiated coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They set a “buy” rating and a $27.00 price objective on the stock. Oppenheimer Holdings, Inc. initiated coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Finally, Raymond James Financial, Inc. initiated coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They set an “outperform” rating and a $25.00 price objective on the stock.

TRADEMARK VIOLATION NOTICE: “Urogen Pharma (URGN) Given $28.00 Average Price Target by Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/06/15/urogen-pharma-urgn-given-28-00-average-price-target-by-analysts.html.

Shares of Urogen Pharma (URGN) opened at 15.72 on Thursday. The company’s market capitalization is $36.23 million. The company’s 50-day moving average is $17.29 and its 200 day moving average is $17.29. Urogen Pharma has a 12 month low of $13.01 and a 12 month high of $20.02.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.